Eagle Pharmaceuticals (EGRX) Misses Q3 EPS by 7c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Eagle Pharmaceuticals (EGRX) PT Lowered to $64 at RBC Capital
November 2, 2018 7:01 AM EDTRBC Capital analyst Randall Stanicky lowered the price target on Eagle Pharmaceuticals (NASDAQ: EGRX) to $64.00 (from $84.00) while maintaining an Outperform rating.
Stanicky said results place a spotlight on recent pipeline setbacks and outlook.
... MorePiper Jaffray Downgrades Eagle Pharmaceuticals (EGRX) to Neutral
October 31, 2018 3:11 AM EDTPiper Jaffray analyst David Amsellem downgraded Eagle Pharmaceuticals (NASDAQ: EGRX) from Overweight to Neutral with a price target of $54.00 (from $82.00).
For an analyst ratings summary and ratings history on Eagle Pharmaceuticals click here. For more ratings news on Eagle Pharmaceuticals click here.
Shares of Eagle Pharmaceuticals closed at $47.50 yesterday.
... MoreEagle Pharmaceuticals (EGRX) Reports Prelim. 3Q EPS Above Consenus, Prelim. 3Q Revenues Below Consensus
October 30, 2018 7:34 AM EDTEagle Pharmaceuticals, Inc. (NASDAQ: EGRX) today provided preliminary financial results and announced that its Board of Directors has approved a new stock repurchase program providing for the repurchase of up to an aggregate of $150 million of Eagles common stock, consisting of (i) up to $50 million in repurchases pursuant to an accelerated... More
Eagle Pharmaceuticals (EGRX) Initiates $50M Accelerated Share Buyback as Part of New $150M Share Buyback Authorization
October 30, 2018 7:31 AM EDTEagle Pharmaceuticals, Inc. (NASDAQ: EGRX) today provided preliminary financial results and announced that its Board of Directors has approved a new stock repurchase program providing for the repurchase of up to an aggregate of $150 million of Eagles common stock, consisting of (i) up to $50 million in repurchases pursuant to an accelerated share repurchase (ASR) transaction with JPMorgan Chase Bank, National Association (JP Morgan) and (ii) up to $100 million in additional repurchases. This reflects the Company's conviction in its business strategy.
The specific... More
